• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

31.26 -0.02 (-0.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗
May 20, 2026
NCR Atleos delivers self-service banking technology and managed services to financial institutions and enterprise clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
May 11, 2026
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Scores 7/10 Fundamental Rating in Affordable Growth Screen ↗
May 11, 2026
Via Chartmill
News headline image
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
May 09, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case ↗
April 18, 2026
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment ↗
March 21, 2026
Via Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case ↗
March 11, 2026
Via Chartmill
News headline image
This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth ↗
May 09, 2026
This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S. market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
May 07, 2026
The Company will Report First Quarter 2026 Financial Results on May 11, 2026 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
May 07, 2026
From Halper Sadeh LLC
Via Business Wire
News headline image
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
May 07, 2026
From Angelini Pharma; Catalyst Pharmaceuticals
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup ↗
March 05, 2026
Via Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout ↗
February 26, 2026
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Beats Q4 Estimates, Issues Conservative 2026 Outlook ↗
February 25, 2026
Via Chartmill
News headline image
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
May 07, 2026
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
April 28, 2026
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Positive Technical Setup ↗
April 14, 2026
Catalyst Pharmaceuticals (CPRX) combines strong growth, high profitability, and a debt-free balance sheet with a positive technical trend, signaling a potential breakout opportunity. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock ↗
April 10, 2026
Catalyst Pharmaceuticals (CPRX) exemplifies affordable growth with strong earnings, a debt-free balance sheet, and a valuation below industry averages. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup ↗
February 07, 2026
Via Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Screens as an Affordable Growth Stock ↗
January 29, 2026
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
March 06, 2026
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
February 25, 2026
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
February 24, 2026
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
February 11, 2026
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case ↗
January 20, 2026
Via Chartmill
News headline image
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
January 24, 2026
Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. 
Via The Motley Fool
Topics ETFs Intellectual Property World Trade
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Fundamentals with a Technical Breakout Setup ↗
January 16, 2026
Via Chartmill
News headline image
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
January 05, 2026
Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? ↗
December 31, 2025
The exercise-and-sell transaction came as the rare disease drugmaker reported strong quarterly results. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Stock Pick ↗
December 22, 2025
Catalyst Pharmaceuticals (CPRX) exemplifies the GARP strategy with strong growth, high profitability, and a reasonable valuation in the biotech sector. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap